We used two human breast cancer cell lines: low-metastatic estrogen receptor (ER)+ MCF-7 cells and highly metastatic ER− MDA-MB-231 cells to compare the efficacy of the RF16 peptide on breast cancer cells with different features. This evidence concerns the gene ESR1 and breast carcinoma.